Skip to main content

Table 2 Baseline characteristics, treatment, and effects of treatment in AAV patients with responder and non-responder

From: Longitudinal immune cell monitoring identified CD14++ CD16+ intermediate monocyte as a marker of relapse in patients with ANCA-associated vasculitis

Variable

Without relapse, n = 20

With relapse, n = 9

P value

Baseline demographic

 Age at diagnosis, years

67 (55–78)

75 (65–80)

0.27

 Male, n (%)

11 (58)

2 (22)

0.070

 PR3-ANCA+ GPA, n (%)

4 (20)

3 (33)

0.65

 MPO-ANCA+ GPA, n (%)

3 (15)

2 (22)

0.64

 ANCA− GPA, n (%)

1 (5)

0 (0)

0.38

 MPO-ANCA+ MPA, n (%)

12 (60)

4 (44)

0.44

 BVAS

11 (8.3–16)

12 (8.5–16)

0.74

Organ involvement

 Ear, nose, throat, n (%)

7 (35)

6 (67)

0.11

 CNS, n (%)

4 (20)

3 (33)

0.43

 PNS, n (%)

2 (10)

3 (33)

0.13

 Kidney, n (%)

10 (50)

2 (22)

0.15

 ILD, n (%)

11 (55)

5 (56)

0.98

Laboratory tests

 ESR, mm/h

102 (48–125)

106 (43–127)

0.77

 WBC, × 103 cells/μL

9.9 (7.1–14)

9.0 (6.3–12)

0.46

 Hemoglobin, g/dL

11 (9.8–13)

11 (9.4–13)

0.51

 Platelet, × 104 cells/μL

33 (26–42)

35 (19–40)

0.51

 CRP, mg/dL

5.2 (1.6–8.5)

8.3 (0.8–11)

0.57

 IgG, mg/dL

1.8 (1.3–2.0)

1.8 (1.2–2.3)

0.55

 RF, IU/L

56 (26–188)

37 (15–93)

0.28

 MPO/PR3-ANCA, IU/L

79 (19–276)

40 (14–51)

0.14

PSL dose

 Initial PSL dose, mg/day

50 (40–60)

35 (30–58)

0.28

 PSL dose at week 24, mg/day

10 (9–13)

17 (11–35)

0.026

 PSL dose at week 52, mg/day

7 (5–9)

10 (10–16)

0.0071

Immunosuppressive drugs

 Induction therapy

IVCY, 7 (35); RTX, 5 (25); AZA, 8 (40)

IVCY, 3 (33); RTX, 3 (33); AZA, 1 (11); MTX, 1 (11)

–

 Maintenance therapy until relapse

RTX, 5 (25); AZA, 10 (50); MTX, 1 (5); Tac, 2 (10)

RTX, 1 (11); AZA, 2 (22); MTX, 1 (11)

–

 Reinduction therapy

–

IVCY, 3 (33); RTX, 2 (22)

–

 Maintenance therapy after reinduction therapy

–

RTX, 1 (11); AZA, 2 (22); Tac, 1 (11)

–

Outcome

 Severe infection, n (%)

4 (20)

6 (67)

0.015

 Death, n (%)

1 (5)

1 (11)

0.56

  1. Continuous data are expressed as median (IQR), and categorical data as number and/or percentage. Continuous variables were compared using the Mann-Whitney U test, and categorical variables using the chi-squared test. Values in bold are statistically significant (P <  0.05). AAV ANCA-associated vasculitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, CNS central nervous system, PNS peripheral nervous system, ESR erythrocyte sedimentation rate, WBC white blood cell, CRP C-reactive protein, RF rheumatoid factor, PSL prednisolone, IVCY intravenous cyclophosphamide, RTX rituximab, AZA azathioprine, MTX methotrexate, Tac tacrolimus